Indoor allergens: Relevance of major allergen measurements and standardization

Journal of Allergy and Clinical Immunology

Volumn 119, Issue 2, 2007, Pages 270-277

  van Ree, Ronald ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

assay differences; biological standardization; immunotherapy; Major allergen measurements; optimal dose; sensitization and tolerization thresholds; standardization

Indexed keywords

ALLERGEN; BET V 1 ALLERGEN; BIRCH POLLEN ALLERGEN; CAN F 1 ALLERGEN; CAT ALLERGEN; DER F 1 ALLERGEN; DER F 2 ALLERGEN; DER P 1 ALLERGEN; DER P 2 ALLERGEN; FEL D 1 ALLERGEN; FOOD ALLERGEN; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM; IMMUNOGLOBULIN E; ISOPROTEIN; MONOCLONAL ANTIBODY; OLE E 1 ALLERGEN; OLIVE POLLEN ALLERGEN; PARIETARIA POLLEN ALLERGEN; PHL P 5A ALLERGEN; PLACEBO; POLLEN ANTIGEN; POLYCLONAL ANTIBODY; RAGWEED ANTIGEN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ALLERGENICITY; ALLERGIC DISEASE; ANTIBODY RESPONSE; ANTIGEN BINDING; ANTIGEN RECOGNITION; BIOLOGICAL MONITORING; BIRCH; CAT; CLINICAL TRIAL; CROSS REACTION; DANDER; DERMATOPHAGOIDES PTERONYSSINUS; DIAGNOSTIC TEST; DOG; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOOD ALLERGY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOASSAY; IMMUNOTHERAPY; MASS; MASS SPECTROMETRY; MEASUREMENT; NONHUMAN; OLIVE; OPTIMAL DRUG DOSE; POLLEN ALLERGY; PRICK TEST; PRIMARY PREVENTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOALLERGOSORBENT TEST; REVIEW; SECONDARY PREVENTION; STANDARDIZATION; THERAPY EFFECT;

AIR POLLUTION, INDOOR; ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOOD HYPERSENSITIVITY; HUMANS;

EID: 33846813797     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.10.033     Document Type: Review

References (73)

1. The use of standardized allergen extracts. American Academy of Allergy, Asthma and Immunology (AAAAI). J Allergy Clin Immunol 99 (1997) 583-586
2. van Ree R. Standardization of allergen extracts-a mission impossible?. Allergy Clin Immunol Int 11 (1999) 55-59
3. van Ree R. Analytic aspects of the standardization of allergenic extracts. Allergy 52 (1997) 795-805
4. King T.P., Hoffman D., Lowenstein H., Marsh D.G., Platts-Mills T.A., and Thomas W. Allergen nomenclature. WHO/IUIS Allergen Nomenclature Subcommittee. Int Arch Allergy Immunol 105 (1994) 224-233
5. Aalberse R.C. Structural biology of allergens. J Allergy Clin Immunol 106 (2000) 228-238
6. Jutel M., Jaeger L., Suck R., Meyer H., Fiebig H., and Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 116 (2005) 608-613
7. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 355 (2006) 1445-1455
8. Thomas W.R., Smith W.A., Hales B.J., Mills K.L., and O'Brien R.M. Characterization and immunobiology of house dust mite allergens. Int Arch Allergy Immunol 129 (2002) 1-18
9. van Ree R., van Leeuwen W.A., Bulder I., Bond J., and Aalberse R.C. Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy. J Allergy Clin Immunol 104 (1999) 1223-1230
10. van Ree R., Dorpema J.W., and Vieths S. Allergy vaccines: a need for standardisation in mass units of major allergen. Pharmeuropa Bio 2005 (2005) 27-30
11. Bousquet J., Lockey R., and Malling H.J. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102 (1998) 558-562
12. Van Metre Jr. T.E., Marsh D.G., Adkinson Jr. N.F., Kagey-Sobotka A., Khattignavong A., Norman Jr. P.S., et al. Immunotherapy for cat asthma. J Allergy Clin Immunol 82 (1988) 1055-1068
13. Creticos P.S., Marsh D.G., Proud D., Kagey-Sobotka A., Adkinson Jr. N.F., Friedhoff L., et al. Responses to ragweed-pollen nasal challenge before and after immunotherapy. J Allergy Clin Immunol 84 (1989) 197-205
14. Haugaard L., Dahl R., and Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 91 (1993) 709-722
15. Alvarez-Cuesta E., Cuesta-Herranz J., Puyana-Ruiz J., Cuesta-Herranz C., and Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo study. J Allergy Clin Immunol 93 (1994) 556-566
16. Creticos P.S., Reed C.E., Norman P.S., Khoury J., Adkinson Jr. N.F., Buncher C.R., et al. Ragweed immunotherapy in adult asthma. N Engl J Med 334 (1996) 501-506
17. Olaguibel J.M., Tabar A.I., Garcia Figueroa B.E., and Cortes C. Immunotherapy with standardized extract of Dermatophagoides pteronyssinus in bronchial asthma: a dose-titration study. Allergy 52 (1997) 168-178
18. Nelson H.S. The use of standardized extracts in allergen immunotherapy. J Allergy Clin Immunol 106 (2000) 41-45
19. Bodtger U., Poulsen L.K., Jacobi H.H., and Malling H.J. The safety and efficacy of subcutaneous birch pollen immunotherapy-a one-year, randomised, double-blind, placebo-controlled study. Allergy 57 (2002) 297-305
20. Nettis E., Giordano D., Pannofino A., Ferrannini A., and Tursi A. Safety of inhalant allergen immunotherapy with mass units-standardized extracts. Clin Exp Allergy 32 (2002) 1745-1749
21. Garcia-Villalmanzo I., Hernandez M.D., Campos A., Giner A.M., Polo F., Cortes C., et al. Immunotherapy with a mass unit Parietaria judaica extract: a tolerance study with evidence of immunological changes to the major allergen Par j 1. J Investig Allergol Clin Immunol 9 (1999) 321-329
22. Gonzalez P., Florido F., Saenz de San P.B., de la T.F., Rico P., and Martin S. Immunotherapy with an extract of Olea europaea quantified in mass units. Evaluation of the safety and efficacy after one year of treatment. J Investig Allergol Clin Immunol 12 (2002) 263-271
23. Ewbank P.A., Murray J., Sanders K., Curran-Everett D., Dreskin S., and Nelson H.S. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol 111 (2003) 155-161
24. Mirone C., Albert F., Tosi A., Mocchetti F., Mosca S., Giorgino M., et al. Efficacy and safety of subcutaneous immunotherapy with a biologically standardized extract of Ambrosia artemisiifolia pollen: a double-blind, placebo-controlled study. Clin Exp Allergy 34 (2004) 1408-1414
25. Nanda A., O'connor M., Anand M., Dreskin S.C., Zhang L., Hines B., et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 114 (2004) 1339-1344
26. Rossi R.E., and Monasterolo G. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)-specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients. Int Arch Allergy Immunol 135 (2004) 44-53
27. Tabar A.I., Echechipia S., Garcia B.E., Olaguibel J.M., Lizaso M.T., Gomez B., et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J Allergy Clin Immunol 116 (2005) 109-118
28. Casanovas M., Martin R., Jimenez C., Caballero R., and Fernandez-Caldas E. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts. Int Arch Allergy Immunol 139 (2006) 153-158
29. Frew A.J., Powell R.J., Corrigan C.J., and Durham S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 319-325
30. Lent A.M., Harbeck R., Strand M., Sills M., Schmidt K., Efaw B., et al. Immunological response to administration of standardized dog allergen extract at differing doses. J Allergy Clin Immunol 118 (2006) 1249-1256
31. La Rosa M., Ranno C., Andre C., Carat F., Tosca M.A., and Canonica G.W. Double-blind placebo-controlled evaluation of sublingual-swallow immunotherapy with standardized Parietaria judaica extract in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 104 (1999) 425-432
32. Pradalier A., Basset D., Claudel A., Couturier P., Wessel F., Galvain S., et al. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis. Allergy 54 (1999) 819-828
33. Bousquet J., Scheinmann P., Guinnepain M.T., Perrin-Fayolle M., Sauvaget J., Tonnel A.B., et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 54 (1999) 249-260
34. Guez S., Vatrinet C., Fadel R., and Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 55 (2000) 369-375
35. Grosclaude M., Bouillot P., Alt R., Leynadier F., Scheinmann P., Rufin P., et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 129 (2002) 248-253
36. Andre C., Perrin-Fayolle M., Grosclaude M., Couturier P., Basset D., Cornillon J., et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis. Evidence for a dose-response relationship. Int Arch Allergy Immunol 131 (2003) 111-118
37. Tonnel A.B., Scherpereel A., Douay B., Mellin B., Leprince D., Goldstein N., et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 59 (2004) 491-497
38. Khinchi M.S., Poulsen L.K., Carat F., Andre C., Hansen A.B., and Malling H.J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 59 (2004) 45-53
39. Rolinck-Werninghaus C., Wolf H., Liebke C., Baars J.C., Lange J., Kopp M.V., et al. A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen. Allergy 59 (2004) 1285-1293
40. Smith H., White P., Annila I., Poole J., Andre C., and Frew A. Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol 114 (2004) 831-837
41. Dahl R., Stender A., and Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61 (2006) 185-190
42. Dahl R., Kapp A., Colombo G., de Monchy J.G., Rak S., Emminger W., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
43. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., and Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 802-809
44. Larsen T.H., Poulsen L.K., Melac M., Combebias A., Andre C., and Malling H.J. Safety and tolerability of grass pollen tablets in sublingual immunotherapy-a phase-1 study. Allergy 61 (2006) 1173-1176
45. Niederberger V., Horak F., Vrtala S., Spitzauer S., Krauth M.T., Valent P., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 101 suppl 2 (2004) 14677-14682
46. Francis J.N., and Larche M. Peptide-based vaccination: where do we stand?. Curr Opin Allergy Clin Immunol 5 (2005) 537-543
47. Batard T., Hrabina A., Bi X.Z., Chabre H., Lemoine P., Couret M.N., et al. Production and proteomic characterization of pharmaceutical-grade Dermatophagoides pteronyssinus and Dermatophagoides farinae extracts for allergy vaccines. Int Arch Allergy Immunol 140 (2006) 295-305
48. van Ree R. Value of monoclonal antibody-based assays: advantages and drawbacks. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 87 (1994) 127-135
49. van Ree R. Monoclonal versus monospecific polyclonal antibodies and purified major allergens: their application in allergen standardization. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 91 (1997) 174-176
50. Hakkaart G.A., Chapman M.D., Aalberse R.C., and van Ree R. Immune-reactivity of recombinant isoforms of the major house dust mite allergen Der p 2. Clin Exp Allergy 28 (1998) 169-174
51. Smith A.M., Benjamin D.C., Derewenda U., Smith W.A., Thomas W.R., and Chapman M.D. Sequence polymorphisms and antibody binding to the group 2 dust mite allergens. Int Arch Allergy Immunol 124 (2001) 61-63
52. van Oort E., Dieker M.C., de Heer P.G., Peltre G., Aalberse R.C., and van Ree R. The major grass pollen group 5 allergen from Dactylis glomerata and its C-terminal split product both behave as dimers: implications for allergen standardization. Int Arch Allergy Immunol 136 (2005) 113-122
53. Helm R.M., Gauerke M.B., Baer H., Lowenstein H., Ford A., Levy D.A., et al. Production and testing of an international reference standard of short ragweed pollen extract. J Allergy Clin Immunol 73 (1984) 790-800
54. Ford A.W., Rawle F.C., Lind P., Spieksma F.T., Lowenstein H., and Platts-Mills T.A. Standardization of Dermatophagoides pteronyssinus: assessment of potency and allergen content in ten coded extracts. Int Arch Allergy Appl Immunol 76 (1985) 58-67
55. Gjesing B., Jager L., Marsh D.G., and Lowenstein H. The international collaborative study establishing the first international standard for timothy (Phleum pratense) grass pollen allergenic extract. J Allergy Clin Immunol 75 (1985) 258-267
56. Ford A., Seagroatt V., Platts-Mills T.A., and Lowenstein H. A collaborative study on the first international standard of Dermatophagoides pteronyssinus (house dust mite) extract. J Allergy Clin Immunol 75 (1985) 676-686
57. Larsen J.N., Ford A., Gjesing B., Levy D., Petrunov B., Silvestri L., et al. The collaborative study of the international standard of dog, Canis domesticus, hair/dander extract. J Allergy Clin Immunol 82 (1988) 318-330
58. Arntzen F.C., Wilhelmsen T.W., Lowenstein H., Gjesing B., Maasch H.J., Stromberg R., et al. The international collaborative study on the first international standard of birch (Betula verrucosa)-pollen extract. J Allergy Clin Immunol 83 (1989) 66-82
59. van Ree R. The CREATE project: EU support for the improvement of allergen standardization in Europe. Allergy 59 (2004) 571-574
60. Lau S., Nickel R., Niggemann B., Gruber C., Sommerfeld C., Illi S., et al. The development of childhood asthma: lessons from the German Multicentre Allergy Study (MAS). Paediatr Respir Rev 3 (2002) 265-272
61. Ronmark E., Perzanowski M., Platts-Mills T., and Lundback B. Four-year incidence of allergic sensitization among schoolchildren in a community where allergy to cat and dog dominates sensitization: report from the Obstructive Lung Disease in Northern Sweden Study Group. J Allergy Clin Immunol 112 (2003) 747-754
62. Ronmark E., Perzanowski M., Platts-Mills T., and Lundback B. Different sensitization profile for asthma, rhinitis, and eczema among 7-8-year-old children: report from the Obstructive Lung Disease in Northern Sweden studies. Pediatr Allergy Immunol 14 (2003) 91-99
63. Perzanowski M.S., Ronmark E., Nold B., Lundback B., and Platts-Mills T.A. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure. J Allergy Clin Immunol 103 (1999) 1018-1024
64. Platts-Mills T., Vaughan J., Squillace S., Woodfolk J., and Sporik R. Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 357 (2001) 752-756
65. von Mutius E., Braun-Fahrlander C., Schierl R., Riedler J., Ehlermann S., Maisch S., et al. Exposure to endotoxin or other bacterial components might protect against the development of atopy. Clin Exp Allergy 30 (2000) 1230-1234
66. Braun-Fahrlander C., Riedler J., Herz U., Eder W., Waser M., Grize L., et al. Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 347 (2002) 869-877
67. Simpson A., John S.L., Jury F., Niven R., Woodcock A., Ollier W.E., et al. Endotoxin exposure, CD14, and allergic disease: an interaction between genes and the environment. Am J Respir Crit Care Med 174 (2006) 386-392
68. Huss K., Adkinson Jr. N.F., Eggleston P.A., Dawson C., Van Natta M.L., and Hamilton R.G. House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program. J Allergy Clin Immunol 107 (2001) 48-54
69. Sicherer S.H., Burks A.W., and Sampson H.A. Clinical features of acute allergic reactions to peanut and tree nuts in children. Pediatrics 102 (1998) e6
70. Holloway J.A., Warner J.O., Vance G.H., Diaper N.D., Warner J.A., and Jones C.A. Detection of house-dust-mite allergen in amniotic fluid and umbilical-cord blood. Lancet 356 (2000) 1900-1902
71. Vadas P., Wai Y., Burks W., and Perelman B. Detection of peanut allergens in breast milk of lactating women. JAMA 285 (2001) 1746-1748
72. Lack G., Fox D., Northstone K., and Golding J. Factors associated with the development of peanut allergy in childhood. N Engl J Med 348 (2003) 977-985
73. Witteman A.M., van L.J., van der Z.J., and Aalberse R.C. Food allergens in house dust. Int Arch Allergy Immunol 107 (1995) 566-568